The big biotech winners from a new Alzheimer's drug

On Monday, the FDA approved Biogen's Alzheimer's drug, called Aduhelm.

View in browser Subscribe The 9 biggest biotech winners after the FDA took an entirely new approach to approve Biogen's Alzheimer's drug On Monday, the FDA approved Biogen's Alzheimer's drug, called Aduhelm. The new and controversial approach that the FDA took to greenlight the drug is helping reignite interest in Alzheimer's research and could make it easier to get other drugs approved in the future. Here are the healthcare firms set to benefit the most. Read now → Email sent to: ipat39@gmail.com   |   Manage preferences   |   Unsubscribe Terms of Service   |   Privacy Policy   |   © 2021 Insider Inc. 1 Liberty Plaza, New York, NY 10006